Stocks and Investing
Stocks and Investing
Thu, October 27, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, October 26, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jack Allen Maintained (TSHA) at Buy with Decreased Target to $21 on, Oct 26th, 2022
Jack Allen of Baird, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Buy with Decreased Target from $26 to $21 on, Oct 26th, 2022.
Jack has made no other calls on TSHA in the last 4 months.
There are 3 other peers that have a rating on TSHA. Out of the 3 peers that are also analyzing TSHA, 0 agree with Jack's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Jack
- Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $18 on, Tuesday, October 25th, 2022
- Laura Chico of "Wedbush" Maintained at Buy with Decreased Target to $5 on, Friday, August 12th, 2022
- Geulah Livshits of "Chardan Capital" Maintained at Strong Buy with Decreased Target to $32 on, Friday, August 12th, 2022
Contributing Sources